Ontology highlight
ABSTRACT: Background
Liver diseases progress faster in human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected persons than HIV-monoinfected persons. The aim of this study was to compare rates of liver fibrosis progression (measured by the aspartate-to-platelet ratio index [APRI]) among HIV-HCV-coinfected users of modern protease inhibitor (PI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens with a backbone of tenofovir/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC).Methods
Data from a Canadian multicenter cohort study were analyzed, including 315 HCV polymerase chain reaction-positive persons who initiated antiretroviral therapy with a PI or NNRTI and a backbone containing either TDF/FTC or ABC/3TC. Multivariate linear regression analyses with generalized estimating equations were performed after propensity score matching to balance covariates across classes of anchor agent.Results
A backbone of TDF/FTC was received by 67% of PI users and 69% of NNRTI users. Both PI and NNRTI use was associated with increases in APRI over time when paired with a backbone of ABC/3TC: 16% per 5 years (95% confidence interval [CI], 4%, 29%) and 11% per 5 years (95% CI, 2%, 20%), respectively. With TDF/FTC use, no clear association was found among PI users (8% per 5 years, 95% CI, -3%, 19%) or NNRTI users (3% per 5 years, 95% CI, -7%, 12%).Conclusions
Liver fibrosis progression was more influenced by the backbone than by the class of anchor agent in HIV-HCV-coinfected persons. Only ABC/3TC-containing regimens were associated with an increase of APRI score over time, regardless of the class of anchor agent used.
SUBMITTER: Brunet L
PROVIDER: S-EPMC4690484 | biostudies-literature | 2016 Jan
REPOSITORIES: biostudies-literature
Brunet Laurence L Moodie Erica E M EEM Young Jim J Cox Joseph J Hull Mark M Cooper Curtis C Walmsley Sharon S Martel-Laferrière Valérie V Rachlis Anita A Klein Marina B MB Cohen Jeff J Conway Brian B Cooper Curtis C Côté Pierre P Cox Joseph J Gill John J Haider Shariq S Sadr Aida A Johnston Lynn L Hull Mark M Montaner Julio J Moodie Erica E Pick Neora N Rachlis Anita A Rouleau Danielle D Sandre Roger R Tyndall Joseph Mark JM Vachon Marie-Louise ML Sanche Steve S Skinner Stewart S Wong David D
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20150923 2
<h4>Background</h4>Liver diseases progress faster in human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected persons than HIV-monoinfected persons. The aim of this study was to compare rates of liver fibrosis progression (measured by the aspartate-to-platelet ratio index [APRI]) among HIV-HCV-coinfected users of modern protease inhibitor (PI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens with a backbone of tenofovir/emtricitabine (TDF/FTC) or abacavir/la ...[more]